nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.166	0.499	CbGbCtD
Paliperidone—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.102	0.306	CbGbCtD
Paliperidone—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0646	0.195	CbGbCtD
Paliperidone—Tonsillitis—Cyclosporine—focal segmental glomerulosclerosis	0.0222	0.0463	CcSEcCtD
Paliperidone—Thrombotic thrombocytopenic purpura—Cyclosporine—focal segmental glomerulosclerosis	0.0196	0.0409	CcSEcCtD
Paliperidone—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.0196	0.0409	CcSEcCtD
Paliperidone—Swollen tongue—Cyclosporine—focal segmental glomerulosclerosis	0.019	0.0398	CcSEcCtD
Paliperidone—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.0121	0.0253	CcSEcCtD
Paliperidone—Muscle contractions involuntary—Cyclosporine—focal segmental glomerulosclerosis	0.0116	0.0242	CcSEcCtD
Paliperidone—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00975	0.0204	CcSEcCtD
Paliperidone—Vaginal discharge—Cyclosporine—focal segmental glomerulosclerosis	0.0092	0.0192	CcSEcCtD
Paliperidone—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00854	0.0179	CcSEcCtD
Paliperidone—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00821	0.0172	CcSEcCtD
Paliperidone—HTR2A—arteriole—focal segmental glomerulosclerosis	0.00722	0.381	CbGeAlD
Paliperidone—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00665	0.0139	CcSEcCtD
Paliperidone—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00646	0.0135	CcSEcCtD
Paliperidone—Breast pain—Cyclosporine—focal segmental glomerulosclerosis	0.00642	0.0134	CcSEcCtD
Paliperidone—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00637	0.0133	CcSEcCtD
Paliperidone—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00633	0.0132	CcSEcCtD
Paliperidone—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00624	0.013	CcSEcCtD
Paliperidone—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.0062	0.013	CcSEcCtD
Paliperidone—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00616	0.0129	CcSEcCtD
Paliperidone—Lacrimation increased—Cyclosporine—focal segmental glomerulosclerosis	0.00607	0.0127	CcSEcCtD
Paliperidone—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.00541	0.0113	CcSEcCtD
Paliperidone—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00541	0.0113	CcSEcCtD
Paliperidone—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00531	0.0111	CcSEcCtD
Paliperidone—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.00501	0.0105	CcSEcCtD
Paliperidone—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00467	0.00976	CcSEcCtD
Paliperidone—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00459	0.00958	CcSEcCtD
Paliperidone—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00452	0.00945	CcSEcCtD
Paliperidone—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00438	0.00916	CcSEcCtD
Paliperidone—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00433	0.00904	CcSEcCtD
Paliperidone—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00416	0.0087	CcSEcCtD
Paliperidone—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00415	0.00867	CcSEcCtD
Paliperidone—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00406	0.00849	CcSEcCtD
Paliperidone—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00403	0.00843	CcSEcCtD
Paliperidone—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.00778	CcSEcCtD
Paliperidone—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00371	0.00776	CcSEcCtD
Paliperidone—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00367	0.00767	CcSEcCtD
Paliperidone—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00358	0.00749	CcSEcCtD
Paliperidone—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00351	0.00734	CcSEcCtD
Paliperidone—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00344	0.0072	CcSEcCtD
Paliperidone—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00338	0.00706	CcSEcCtD
Paliperidone—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.00704	CcSEcCtD
Paliperidone—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00328	0.00686	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00326	0.00682	CcSEcCtD
Paliperidone—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.00678	CcSEcCtD
Paliperidone—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.0032	0.00668	CcSEcCtD
Paliperidone—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.00664	CcSEcCtD
Paliperidone—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00317	0.00662	CcSEcCtD
Paliperidone—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00315	0.00658	CcSEcCtD
Paliperidone—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00313	0.00654	CcSEcCtD
Paliperidone—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00313	0.00654	CcSEcCtD
Paliperidone—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00312	0.00653	CcSEcCtD
Paliperidone—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00305	0.00638	CcSEcCtD
Paliperidone—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00636	CcSEcCtD
Paliperidone—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00636	CcSEcCtD
Paliperidone—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00619	CcSEcCtD
Paliperidone—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00295	0.00617	CcSEcCtD
Paliperidone—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00294	0.00614	CcSEcCtD
Paliperidone—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00282	0.00589	CcSEcCtD
Paliperidone—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.00585	CcSEcCtD
Paliperidone—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.0058	CcSEcCtD
Paliperidone—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00276	0.00577	CcSEcCtD
Paliperidone—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00276	0.00576	CcSEcCtD
Paliperidone—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00262	0.00548	CcSEcCtD
Paliperidone—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00261	0.00545	CcSEcCtD
Paliperidone—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00255	0.00533	CcSEcCtD
Paliperidone—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00253	0.00529	CcSEcCtD
Paliperidone—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00252	0.00527	CcSEcCtD
Paliperidone—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00248	0.00519	CcSEcCtD
Paliperidone—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.00515	CcSEcCtD
Paliperidone—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00245	0.00511	CcSEcCtD
Paliperidone—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00241	0.00504	CcSEcCtD
Paliperidone—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.00502	CcSEcCtD
Paliperidone—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.00501	CcSEcCtD
Paliperidone—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00238	0.00497	CcSEcCtD
Paliperidone—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00492	CcSEcCtD
Paliperidone—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.00482	CcSEcCtD
Paliperidone—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.00479	CcSEcCtD
Paliperidone—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00227	0.00475	CcSEcCtD
Paliperidone—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.00473	CcSEcCtD
Paliperidone—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.0047	CcSEcCtD
Paliperidone—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.00467	CcSEcCtD
Paliperidone—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00221	0.00461	CcSEcCtD
Paliperidone—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.0022	0.0046	CcSEcCtD
Paliperidone—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00219	0.00458	CcSEcCtD
Paliperidone—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00214	0.00446	CcSEcCtD
Paliperidone—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.00443	CcSEcCtD
Paliperidone—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00211	0.00442	CcSEcCtD
Paliperidone—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00435	CcSEcCtD
Paliperidone—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00435	CcSEcCtD
Paliperidone—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00435	CcSEcCtD
Paliperidone—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00434	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00432	CcSEcCtD
Paliperidone—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00206	0.0043	CcSEcCtD
Paliperidone—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.00426	CcSEcCtD
Paliperidone—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00201	0.00421	CcSEcCtD
Paliperidone—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00417	CcSEcCtD
Paliperidone—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00417	CcSEcCtD
Paliperidone—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00415	CcSEcCtD
Paliperidone—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.00409	CcSEcCtD
Paliperidone—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.00409	CcSEcCtD
Paliperidone—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.00405	CcSEcCtD
Paliperidone—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.00398	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.0038	CcSEcCtD
Paliperidone—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00378	CcSEcCtD
Paliperidone—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.00375	CcSEcCtD
Paliperidone—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00372	CcSEcCtD
Paliperidone—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00371	CcSEcCtD
Paliperidone—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00176	0.00367	CcSEcCtD
Paliperidone—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00174	0.00363	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.0036	CcSEcCtD
Paliperidone—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.0036	CcSEcCtD
Paliperidone—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00357	CcSEcCtD
Paliperidone—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00357	CcSEcCtD
Paliperidone—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00165	0.00344	CcSEcCtD
Paliperidone—ADRA1B—kidney—focal segmental glomerulosclerosis	0.00164	0.0867	CbGeAlD
Paliperidone—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.00341	CcSEcCtD
Paliperidone—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.00332	CcSEcCtD
Paliperidone—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.0033	CcSEcCtD
Paliperidone—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.0033	CcSEcCtD
Paliperidone—HTR2A—endothelium—focal segmental glomerulosclerosis	0.00148	0.0782	CbGeAlD
Paliperidone—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00308	CcSEcCtD
Paliperidone—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.00299	CcSEcCtD
Paliperidone—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.00295	CcSEcCtD
Paliperidone—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00286	CcSEcCtD
Paliperidone—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.00276	CcSEcCtD
Paliperidone—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00265	CcSEcCtD
Paliperidone—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00263	CcSEcCtD
Paliperidone—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00263	CcSEcCtD
Paliperidone—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00261	CcSEcCtD
Paliperidone—HTR1D—kidney—focal segmental glomerulosclerosis	0.0012	0.0634	CbGeAlD
Paliperidone—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00248	CcSEcCtD
Paliperidone—ADRA2C—nephron tubule—focal segmental glomerulosclerosis	0.001	0.0528	CbGeAlD
Paliperidone—ADRA2C—kidney—focal segmental glomerulosclerosis	0.000879	0.0464	CbGeAlD
Paliperidone—ADRA2C—cortex of kidney—focal segmental glomerulosclerosis	0.000856	0.0452	CbGeAlD
Paliperidone—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.000837	0.0442	CbGeAlD
Paliperidone—CYP3A5—kidney—focal segmental glomerulosclerosis	0.000736	0.0388	CbGeAlD
Paliperidone—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.000717	0.0378	CbGeAlD
Paliperidone—ADRA2A—cortex of kidney—focal segmental glomerulosclerosis	0.000683	0.0361	CbGeAlD
Paliperidone—HTR2A—kidney—focal segmental glomerulosclerosis	0.000596	0.0315	CbGeAlD
Paliperidone—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000552	0.0291	CbGeAlD
Paliperidone—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000543	0.0287	CbGeAlD
Paliperidone—ADRA2A—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000112	0.000657	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000112	0.000656	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000112	0.000656	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00011	0.000647	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00011	0.000646	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00011	0.000645	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00011	0.000644	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000109	0.000642	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000108	0.000633	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000108	0.000633	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000108	0.000632	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000107	0.00063	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000106	0.000623	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000105	0.000617	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000104	0.000612	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000104	0.000612	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000104	0.000611	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000103	0.000606	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000103	0.000603	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000103	0.000603	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000103	0.000602	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000102	0.000601	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000102	0.000599	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000102	0.000598	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000101	0.000594	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000101	0.000591	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.0001	0.00059	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.0001	0.000587	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.87e-05	0.000579	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	9.86e-05	0.000579	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.83e-05	0.000577	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	9.81e-05	0.000576	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.78e-05	0.000574	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.78e-05	0.000574	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.72e-05	0.000571	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.71e-05	0.00057	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	9.56e-05	0.000561	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	9.54e-05	0.00056	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—LIPC—focal segmental glomerulosclerosis	9.52e-05	0.000559	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.51e-05	0.000558	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.51e-05	0.000558	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	9.47e-05	0.000556	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.46e-05	0.000555	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	9.43e-05	0.000553	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	9.43e-05	0.000553	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—ALB—focal segmental glomerulosclerosis	9.41e-05	0.000552	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	9.39e-05	0.000551	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.36e-05	0.000549	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	9.34e-05	0.000548	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	9.32e-05	0.000547	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.31e-05	0.000546	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	9.3e-05	0.000546	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	9.28e-05	0.000544	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	9.13e-05	0.000535	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	8.95e-05	0.000525	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	8.91e-05	0.000523	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	8.74e-05	0.000513	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	8.73e-05	0.000512	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	8.66e-05	0.000508	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	8.66e-05	0.000508	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	8.63e-05	0.000507	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	8.62e-05	0.000506	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.58e-05	0.000504	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	8.54e-05	0.000501	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	8.53e-05	0.0005	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	8.52e-05	0.0005	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	8.51e-05	0.0005	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	8.5e-05	0.000499	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	8.49e-05	0.000498	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	8.48e-05	0.000498	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	8.48e-05	0.000497	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.44e-05	0.000496	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.43e-05	0.000494	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CTGF—focal segmental glomerulosclerosis	8.38e-05	0.000492	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	8.37e-05	0.000491	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	8.34e-05	0.000489	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	8.32e-05	0.000488	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—LPL—focal segmental glomerulosclerosis	8.29e-05	0.000486	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.27e-05	0.000485	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	8.23e-05	0.000483	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	8.22e-05	0.000482	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	8.18e-05	0.00048	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	8.12e-05	0.000476	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.99e-05	0.000469	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.95e-05	0.000467	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	7.86e-05	0.000461	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.85e-05	0.000461	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—TGFB1—focal segmental glomerulosclerosis	7.85e-05	0.00046	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.83e-05	0.000459	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.79e-05	0.000457	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	7.75e-05	0.000455	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	7.74e-05	0.000454	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	7.73e-05	0.000453	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.73e-05	0.000453	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	7.72e-05	0.000453	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.69e-05	0.000451	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	7.68e-05	0.000451	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	7.68e-05	0.000451	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	7.57e-05	0.000444	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.56e-05	0.000444	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.52e-05	0.000441	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.48e-05	0.000439	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.41e-05	0.000435	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—TGFB1—focal segmental glomerulosclerosis	7.33e-05	0.00043	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.31e-05	0.000429	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.27e-05	0.000427	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.22e-05	0.000423	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.19e-05	0.000422	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.16e-05	0.00042	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—LPL—focal segmental glomerulosclerosis	7.16e-05	0.00042	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.1e-05	0.000417	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.09e-05	0.000416	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AGT—focal segmental glomerulosclerosis	7.09e-05	0.000416	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.08e-05	0.000416	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.08e-05	0.000415	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	7.04e-05	0.000413	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	6.95e-05	0.000408	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.94e-05	0.000407	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.83e-05	0.000401	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	6.81e-05	0.0004	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	6.72e-05	0.000394	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.6e-05	0.000387	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.6e-05	0.000387	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6.55e-05	0.000384	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.49e-05	0.000381	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.48e-05	0.00038	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	6.46e-05	0.000379	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6.42e-05	0.000376	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	6.4e-05	0.000376	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.37e-05	0.000374	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.36e-05	0.000373	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.34e-05	0.000372	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6.31e-05	0.00037	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	6.21e-05	0.000364	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	6.18e-05	0.000363	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.17e-05	0.000362	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—LPL—focal segmental glomerulosclerosis	6.15e-05	0.000361	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.15e-05	0.000361	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AGT—focal segmental glomerulosclerosis	6.12e-05	0.000359	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.07e-05	0.000356	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.07e-05	0.000356	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	6.07e-05	0.000356	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.98e-05	0.000351	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—TGFB1—focal segmental glomerulosclerosis	5.95e-05	0.000349	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.91e-05	0.000347	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.89e-05	0.000346	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.86e-05	0.000344	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.83e-05	0.000342	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—LPL—focal segmental glomerulosclerosis	5.81e-05	0.000341	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.68e-05	0.000334	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.67e-05	0.000332	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.61e-05	0.000329	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.6e-05	0.000328	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.58e-05	0.000327	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.51e-05	0.000323	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.49e-05	0.000322	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.48e-05	0.000322	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	5.46e-05	0.000321	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.45e-05	0.00032	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.43e-05	0.000319	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.39e-05	0.000316	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.34e-05	0.000313	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.34e-05	0.000313	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.33e-05	0.000313	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	5.33e-05	0.000313	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.29e-05	0.00031	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.26e-05	0.000309	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.25e-05	0.000308	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.23e-05	0.000307	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.14e-05	0.000302	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.12e-05	0.0003	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.06e-05	0.000297	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.06e-05	0.000297	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.05e-05	0.000296	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.04e-05	0.000296	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.03e-05	0.000295	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.01e-05	0.000294	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AGT—focal segmental glomerulosclerosis	4.97e-05	0.000292	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.95e-05	0.000291	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.89e-05	0.000287	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.86e-05	0.000285	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.86e-05	0.000285	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.73e-05	0.000278	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.73e-05	0.000278	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—ALB—focal segmental glomerulosclerosis	4.7e-05	0.000276	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.67e-05	0.000274	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.65e-05	0.000273	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.64e-05	0.000273	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.6e-05	0.00027	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.57e-05	0.000268	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.56e-05	0.000268	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	4.56e-05	0.000267	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.47e-05	0.000263	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.29e-05	0.000252	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.22e-05	0.000248	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.21e-05	0.000247	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.21e-05	0.000247	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.18e-05	0.000245	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.16e-05	0.000244	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.13e-05	0.000243	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.09e-05	0.00024	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.07e-05	0.000239	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	4.06e-05	0.000238	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.05e-05	0.000237	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.02e-05	0.000236	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.94e-05	0.000231	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.87e-05	0.000227	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.84e-05	0.000225	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—ALB—focal segmental glomerulosclerosis	3.82e-05	0.000224	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	3.79e-05	0.000222	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.62e-05	0.000213	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.57e-05	0.00021	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	3.57e-05	0.00021	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.57e-05	0.00021	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.51e-05	0.000206	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.51e-05	0.000206	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	3.5e-05	0.000205	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.44e-05	0.000202	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.44e-05	0.000202	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.37e-05	0.000198	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.32e-05	0.000195	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.29e-05	0.000193	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	3.24e-05	0.00019	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.23e-05	0.000189	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.2e-05	0.000188	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.12e-05	0.000183	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.1e-05	0.000182	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.01e-05	0.000177	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.99e-05	0.000175	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.97e-05	0.000174	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.95e-05	0.000173	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.74e-05	0.00016	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.69e-05	0.000158	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.69e-05	0.000158	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.66e-05	0.000156	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.64e-05	0.000155	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.57e-05	0.000151	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.55e-05	0.00015	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	2.49e-05	0.000146	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.48e-05	0.000146	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	2.48e-05	0.000145	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.45e-05	0.000144	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.45e-05	0.000143	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.25e-05	0.000132	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.22e-05	0.00013	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.21e-05	0.00013	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.17e-05	0.000127	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.12e-05	0.000124	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.02e-05	0.000118	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.63e-05	9.54e-05	CbGpPWpGaD
